{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:13:27Z","timestamp":1794510807163,"version":"4.9.1"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Esketamine nasal spray, administered in conjunction with an oral antidepressant, is approved for treatment-resistant depression (TRD). However, the efficacy of esketamine nasal spray administered as monotherapy for patients with TRD has not yet been evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of esketamine monotherapy compared to placebo in reducing depressive symptoms in patients with TRD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>\n                      This phase 4, double-blind, placebo-controlled randomized clinical trial was conducted from November 2020 to January 2024 at 51 outpatient centers in the US. Adults with major depressive disorder (\n                      <jats:italic>DSM-5<\/jats:italic>\n                      criteria) without psychotic features who experienced inadequate response (\u226425% improvement) to 2 or more oral antidepressants during the current depressive episode were eligible for inclusion. Data analyses were conducted from March 1, 2024, to July 8, 2024.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>After a 2-week or longer antidepressant-free period, participants were randomized at a 1:1:2 ratio to fixed-dose intranasal esketamine (56 mg or 84 mg) or matching intranasal placebo, administered twice weekly for 4 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Change in Montgomery-\u00c5sberg Depression Rating Scale (MADRS) score from baseline to day 28 (primary efficacy end point) and to 24 hours post\u2013first dose (day 2; key secondary efficacy end point) were analyzed by a mixed-effects model using repeated measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this multicenter randomized clinical trial, 378 participants who met prerandomization MADRS severity criteria received 1 or more study drug doses (esketamine, 56 mg [n\u2009=\u200986]; esketamine, 84 mg [n\u2009=\u200995]; or placebo [n\u2009=\u2009197]). Mean (SD) participant age was 45.4 (14.1) years, 231 participants (61.1%) were female, and baseline mean (range) MADRS total score was 37.3 (28-50). At day 28, the least-square (LS) mean difference (SE) between esketamine and placebo was \u22125.1 (1.42) (95% CI, \u22127.91 to \u22122.33) for the 56-mg dose and \u22126.8 (1.38) (95% CI, \u22129.48 to \u22124.07) for the 84-mg dose (for each, 2-sided\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Observed effect sizes were 0.48 and 0.63 for the 56-mg and 84-mg dose groups, respectively. At day 2 (approximately 24 hours post\u2013first dose), the between-group difference was significant for both esketamine doses: \u22123.8 (1.29) (95% CI, \u22126.29 to \u22121.22; 2-sided\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.004) for 56 mg and \u22123.4 (1.24) (95% CI, \u22125.89 to \u22121.00; 2-sided\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.006) for 84 mg. The most common treatment-emergent adverse events reported for esketamine (combined doses) were nausea (56 participants [24.8%]), dissociation (55 [24.3%]), dizziness (49 [21.7%]), and headache (43 [19.0%]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>According to results of this multicenter, double-blind randomized clinical trial, esketamine monotherapy may expand treatment options for adult patients with TRD by addressing an unmet need of patients experiencing treatment-limiting tolerability concerns and nonresponse with oral antidepressants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT04599855?cond=NCT04599855&amp;amp;amp;rank=1\">NCT04599855<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2025.1317","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:00:21Z","timestamp":1751454021000},"page":"877","source":"Crossref","is-referenced-by-count":59,"title":["Esketamine Monotherapy in Adults With Treatment-Resistant Depression"],"prefix":"10.1001","volume":"82","author":[{"given":"Adam","family":"Janik","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Johnson & Johnson, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Clinical Biostatistics, Johnson & Johnson, Titusville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Lane","sequence":"additional","affiliation":[{"name":"Department of Clinical Biostatistics, Johnson & Johnson, Titusville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanina","family":"Popova","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Johnson & Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne C.","family":"Drevets","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Johnson & Johnson, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla M.","family":"Canuso","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Johnson & Johnson, Titusville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Macaluso","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory W.","family":"Mattingly","sequence":"additional","affiliation":[{"name":"Midwest Research Group\u2013St Charles Psychiatric Associates, St Charles, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Shelton","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham School of Medicine, Huntsville Regional Medical Campus, Huntsville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Zajecka","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Rush University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Jing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Johnson & Johnson, Titusville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10258","key":"yoi250033r1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"yoi250033r3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis.","volume":"72","author":"Walker","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"yoi250033r4","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"1","key":"yoi250033r7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3111\/13696998.2012.724745","article-title":"Medicare patient experience with vagus nerve stimulation for treatment-resistant depression.","volume":"16","author":"Feldman","year":"2013","journal-title":"J Med Econ"},{"issue":"8","key":"yoi250033r8","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3171","article-title":"Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone.","volume":"13","author":"Kern","year":"2023","journal-title":"Brain Behav"},{"issue":"2","key":"yoi250033r9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1176\/ajp.2007.164.2.201","article-title":"STAR*D: what have we learned?","volume":"164","author":"Rush","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"5","key":"yoi250033r11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000447034","article-title":"The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature.","volume":"85","author":"Carvalho","year":"2016","journal-title":"Psychother Psychosom"},{"key":"yoi250033r12","doi-asserted-by":"publisher","DOI":"10.1017\/S1463423623000038","article-title":"Self-reported reasons for reducing or stopping antidepressant medications in primary care: thematic analysis of the diamond longitudinal study.","volume":"24","author":"Coe","year":"2023","journal-title":"Prim Health Care Res Dev"},{"issue":"4","key":"yoi250033r13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1345\/aph.1A254","article-title":"Discontinuing or switching selective serotonin-reuptake inhibitors.","volume":"36","author":"Bull","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"7","key":"yoi250033r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.23746","article-title":"Reasons for discontinuation or change of selective serotonin reuptake inhibitors in online drug reviews.","volume":"6","author":"Golder","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"yoi250033r15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.31887\/DCNS.2008.10.4\/kkelly","article-title":"Toward achieving optimal response: understanding and managing antidepressant side effects.","volume":"10","author":"Kelly","year":"2008","journal-title":"Dialogues Clin Neurosci"},{"issue":"1","key":"yoi250033r16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1176\/appi.ajp.163.1.101","article-title":"Continuity of antidepressant treatment for adults with depression in the United States.","volume":"163","author":"Olfson","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"4","key":"yoi250033r17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.eurpsy.2009.07.012","article-title":"Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database.","volume":"25","author":"Serna","year":"2010","journal-title":"Eur Psychiatry"},{"issue":"2","key":"yoi250033r18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial.","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"yoi250033r19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial.","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"yoi250033r20","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1).","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"yoi250033r21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3.","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"yoi250033r22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study.","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi250033r23","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2).","volume":"81","author":"Wajs","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"yoi250033r25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"1","key":"yoi250033r26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA).","volume":"192","author":"Williams","year":"2008","journal-title":"Br J Psychiatry"},{"issue":"18","key":"yoi250033r27","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","article-title":"Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. primary care evaluation of mental disorders. Patient Health Questionnaire.","volume":"282","author":"Spitzer","year":"1999","journal-title":"JAMA"},{"issue":"7","key":"yoi250033r29","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","article-title":"Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA\u2019s pediatric suicidal risk analysis of antidepressants.","volume":"164","author":"Posner","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"1","key":"yoi250033r30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ph3010019","article-title":"The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments.","volume":"3","author":"Machado-Vieira","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"yoi250033r31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.euroneuro.2008.06.003","article-title":"A regulatory apologia\u2013a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants.","volume":"18","author":"Melander","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"yoi250033r32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/YIC.0b013e32832a8eb2","article-title":"Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?","volume":"24","author":"Montgomery","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"yoi250033r33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41386-023-01600-9","article-title":"How should we design future mechanistic and\/or efficacy clinical trials?","volume":"49","author":"Fava","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"yoi250033r35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jad.2020.03.106","article-title":"Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: number needed to treat, number needed to harm, and likelihood to be helped or harmed.","volume":"271","author":"Citrome","year":"2020","journal-title":"J Affect Disord"},{"key":"yoi250033r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101505","article-title":"Assessment of blinding in randomized controlled trials of antidepressants for depressive disorders 2000-2020: a systematic review and meta-analysis.","volume":"50","author":"Lin","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"4","key":"yoi250033r38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/ijnp\/pyab084","article-title":"Relationship between dissociation and antidepressant effects of esketamine nasal spray in patients with treatment-resistant depression.","volume":"25","author":"Chen","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"yoi250033r39","first-page":"79","article-title":"Consistently modest antidepressant effects in clinical trials: the role of regulatory requirements.","volume":"51","author":"Khan","year":"2021","journal-title":"Psychopharmacol Bull"},{"issue":"8","key":"yoi250033r40","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","article-title":"Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.","volume":"48","author":"Zaki","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"yoi250033r41","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/13696998.2023.2188845","article-title":"Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans.","volume":"26","author":"Joshi","year":"2023","journal-title":"J Med Econ"},{"issue":"8","key":"yoi250033r42","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/03007995.2023.2239045","article-title":"Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.","volume":"39","author":"Teeple","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"yoi250033r28","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"yoi250033r37","author":"Williams","year":"2025"},{"key":"yoi250033r2","unstructured":"World Health Organization. Depression and other common mental disorders: global health estimates. Accessed October 28, 2024. https:\/\/www.who.int\/publications\/i\/item\/depression-global-health-estimates"},{"key":"yoi250033r5","unstructured":"Center for Drug Evaluation and Research, US Food and Drug Administration. Major depressive disorder: developing drugs for treatment. Accessed October 28, 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/major-depressive-disorder-developing-drugs-treatment"},{"key":"yoi250033r6","unstructured":"European Medicines Agency. Clinical investigation of medicinal products in the treatment of depression \u2013Scientific guideline. Accessed October 28, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-2_en.pdf"},{"key":"yoi250033r10","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. Accessed October 28, 2024. https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf"},{"key":"yoi250033r24","unstructured":"Spravato\u00ae (esketamine) nasal spray. Prescribing information. Janssen Pharmaceutical Companies; 2023. Accessed October 28, 2024. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/SPRAVATO-pi.pdf"},{"key":"yoi250033r34","unstructured":"Fu? DJ, Lopena? O, Quach? P, Zaki? N, Sun? L. A post hoc analysis of patients who received esketamine nasal spray monotherapy in an open-label safety extension study (SUSTAIN-3) (abstract TH29). Abstract presented at: American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; May 31-June 3, 2022; Scottsdale, Arizona. Accessed October 28, 2024. https:\/\/pmg.joynadmin.org\/documents\/1005\/628e68149557aa5a02655c33.pdf"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2836115\/jamapsychiatry_janik_2025_oi_250033_1755883033.86117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T15:00:46Z","timestamp":1756911646000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2836115"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.1317","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}